Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C

References

• Brown RS Jr, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl. 9(11), S10–S13 (2003).
   PubMed Web of Science ®Google Scholar
• Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 52(2), 436–442 (2010).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns MP, Muir AJ et al.; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362(14), 1292–1303 (2010).
   PubMed Web of Science ®Google Scholar
• Hézode C, Forestier N, Dusheiko G et al.; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360(18), 1839–1850 (2009).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 35(3), 704–708 (2002).
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J et al.; SPRINT-1 Investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet 376(9742), 705–716 (2010).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC et al.; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360(18), 1827–1838 (2009).
   PubMed Web of Science ®Google Scholar
• Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 41(4), 790–800 (2005).
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E et al.; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1207–1217 (2011).
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G et al.; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364(25), 2405–2416 (2011).
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364(13), 1195–1206 (2011).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S et al.; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364(25), 2417–2428 (2011).
   PubMed Web of Science ®Google Scholar
• Perrillo R, Rothstein KD, Rubin R et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J. Viral Hepat. 11(2), 157–165 (2004).
   PubMed Web of Science ®Google Scholar
• Cotler SJ, Patil R, McNutt RA et al. Patients’ values for health states associated with hepatitis C and physicians’ estimates of those values. Am. J. Gastroenterol. 96(9), 2730–2736 (2001).
   PubMed Web of Science ®Google Scholar
• Devine EB, Cross JT, Kowdley KV, Sullivan SD. The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin. Curr. Med. Res. Opin. 23(6), 1463–1472 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang H, Mehra M, DiBello J. Increasing chronic hepatitis C treatment rate is a cost-saving strategy. Presented at: The 14th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Orlando, FL, USA, 16–20 May 2009.
   Google Scholar
• Zhang H, Mehra M, DiBello J. US hepatitis C burden assessment from a transition model. Presented at: The 14th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Orlando, FL, USA, 16–20 May 2009.
   Google Scholar
• Afdhal NH, Dieterich DT, Pockros PJ et al.; Proactive Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 126(5), 1302–1311 (2004).
   PubMed Web of Science ®Google Scholar
• Chaiwat O, Lang JD, Vavilala MS et al. Early packed red blood cell transfusion and acute respiratory distress syndrome after trauma. Anesthesiology 110(2), 351–360 (2009).
   PubMed Web of Science ®Google Scholar
• Martín-Santos R, Díez-Quevedo C, Castellví P et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment. Pharmacol. Ther. 27(3), 257–265 (2008).
   PubMed Web of Science ®Google Scholar
• Dan AA, Martin LM, Crone C et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J. Hepatol. 44(3), 491–498 (2006).
   PubMed Web of Science ®Google Scholar
• Hollander A, Foster GR, Weiland O. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand. J. Gastroenterol. 41(5), 577–585 (2006).
   PubMed Web of Science ®Google Scholar
• Dan AA, Kallman JB, Wheeler A et al. Health-related quality of life in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 26(6), 815–820 (2007).
   PubMed Web of Science ®Google Scholar
• Hassanein T, Cooksley G, Sulkowski M et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J. Hepatol. 40(4), 675–681 (2004).
   PubMed Web of Science ®Google Scholar
• Sjogren MH, Sjogren R Jr, Lyons MF et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Dig. Dis. Sci. 52(6), 1540–1547 (2007).
   PubMed Web of Science ®Google Scholar